EUSA Pharma announced Nov. 18 that it had received approval from FDA for its acute lymphoblastic leukemia (ALL) treatment Erwinaze (asparaginase Erwinia chrysanthemi), an alternative for pediatric patients who have developed a hypersensitivity to the normal course of therapy.
Most patients with the bone marrow cancer -- ALL affects about 6,000 people, both children and adults, annually – are...